Inside Innovation

Seattle-based health tech startup PreemptiveAI raised $6.4 million in funding and announced a partnership with Duke University to test its predictive healthcare technology. The platform

The Access to Advanced Health Institute (AAHI) in Seattle has secured the first phase of up to $12.7 million in funding from the Medical CBRN

Seattle-based Perspective Therapeutics Inc. recently raised $87.4 million through a private placement, following a $89.8 million fundraising effort in January. This financing includes acquiring a

A recent issue of the Washington Department of Commerce’s ‘Choose Washington’ magazine, highlights Washington’s fast-growing life science industry. According to the article, life science companies

The University of Washington (UW)’s CoMotion recently hosted an event featuring an interview with David Baker, the director of UW’s Institute of Protein Design and

Bristol Myers Squibb, which has facilities in Seattle, recently announced new data from its Phase III DAYBREAK clinical trial for multiple sclerosis treatment (MS). According

Seattle has ranked among the Top 20 happiest cities in America, according to a new study. WalletHub ranked 182 of the largest cities in the U.S. based

Following its acquisition of Seattle-based Seagen, Pfizer has systemically laid out its new oncology strategy and aims to have at least eight blockbuster cancer drugs by

AstraZeneca announced the closing of a $1.1 billion acquisition deal of Icosavax, a Seattle-based biopharmaceutical company. Icosavax’s brand will be absorbed into the larger company

The University of Washington’s (UW) tech transfer office, CoMotion, has facilitated the creation of seven startups since July of last year. These companies, all in

Sana Biotechnology, based in Seattle, published preclinical data demonstrating the company successfully controlled glucose levels in a diabetic primate through genetically engineered pancreatic islet cells.

ProfoundBio, a Seattle-based biotech company on a mission to redefine cancer treatment, announced a $112 million Series B round. According to Erin Lavelle, chief operating